Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0777 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Drug |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK0777 | DRUG | - |
| Comparator: placebo (unspecified) | DRUG | Duration of Treatment: 4 weeks |
| Placebo (unspecified) | DRUG | matching placebo |
Inclusion Criteria: * Have been diagnosed with Generalized Anxiety Disorder * Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study Exclusion Criteria: * History of drug or alcohol abuse * Hav...
MK0777 is an investigational small molecule being developed for the treatment of anxiety disorders, specifically generalized anxiety disorder. It has been studied in Phase 2 clinical trials in adult outpatients with these conditions. The drug is not approved and remains in clinical development.
MK0777 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company has sponsored multiple Phase 2 clinical trials evaluating the drug for the treatment of generalized anxiety disorder and other anxiety disorders.
MK0777 is in Phase 2 clinical development. All completed trials for the drug are Phase 2 studies. It is an investigational agent and has not received FDA approval. The development program includes several completed trials in patients with generalized anxiety disorder.
MK0777 has been studied in several completed Phase 2 trials, including NCT00539578, NCT00543920, NCT00546624, and NCT00703833. These trials evaluated the drug in patients with generalized anxiety disorder and other anxiety disorders, with total enrollment across studies exceeding 300 participants.
MK0777 is also referred to as GEM in some clinical trial contexts, specifically as a gel extrusion module formulation. Trial NCT00546624 and NCT00703833 reference GEM doses of 1.5 mg to 4.5 mg twice daily in the treatment of generalized anxiety disorder.